知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.026 秒)

    PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
    1.
    发明授权
    PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders 失效
    用于治疗血脂异常和其他脂质障碍的PPARα选择性化合物

    公开(公告)号：US07297715B2

    公开(公告)日：2007-11-20

    申请号：US10522646

    申请日：2003-07-25

    申请人： Ranjit C. Desai ,  Soumya Sahoo

    发明人： Ranjit C. Desai ,  Soumya Sahoo

    IPC分类号： A61K31/352 ,  C07D311/04

    CPC分类号： C07D311/04 ,  A61K45/06 ,  C07D311/16 ,  C07D311/18 ,  C07D311/58

    摘要： A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis

    摘要翻译： 具有以下所示结构的一系列色烯和色烯化合物及其药学上可接受的盐可用作治疗化合物，特别是用于治疗和控制高脂血症，高胆固醇血症，血脂异常和其它脂质疾病，并延迟其发作或减少 与这些疾病相关的病症和后遗症的风险，如动脉粥样硬化

    Saccharin derivative proteolytic enzyme inhibitors
    6.
    发明授权
    Saccharin derivative proteolytic enzyme inhibitors 失效
    糖精衍生蛋白水解酶抑制剂

    公开(公告)号：US5464852A

    公开(公告)日：1995-11-07

    申请号：US289113

    申请日：1994-08-11

    申请人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    发明人： Richard P. Dunlap ,  Albert J. Mura ,  Dennis J. Hlasta ,  Ranjit C. Desai ,  Lee H. Latimer ,  Chakrapani Subramanyam

    IPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541 ,  A61K31/425 ,  A61K31/41 ,  C07D249/04

    CPC分类号： C07D275/06 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07F9/6541

    摘要： Compounds having the structural formula ##STR1## wherein L is N, O or SO.sub.n wherein n is 0, 1 or 2;L--R.sup.1 is a leaving group, H--L--R.sup.1 is the conjugate acid thereof and,when L is N, H--L--R.sup.1 has a pK.sub.a value less than or equal to 6, when L is O, H--L--R.sup.1 has a pK.sub.a value less than or equal to to 8, and when L is SO.sub.n, H--L--R.sup.1 has a pK.sub.a value less than or equal to 5;R.sup.2 is primary or secondary alkyl of two to four carbon atoms, primary alkylamino of one to three carbon atoms, primary alkylmethylamino of two to four carbon atoms, diethylamino or primary alkoxy of one to three carbon atoms; andR.sup.3 is from one to three of a variety of substituents at any or all of the 5-, 6- and 7-positions;or a pharmaceutically acceptable acid addition salt thereof if the compound has a basic functional group or a pharmaceutically acceptable base addition salt thereof if the compound has an acidic functional group,which inhibit the enzymatic activity of proteolytic enzymes, and processes for preparation thereof, method of use thereof in treatment of degenerative diseases and pharmaceutical compositions thereof are disclosed.

    摘要翻译： 具有式I的结构式的化合物，其中L是N，O或SO，其中n是0,1或2; L-R1是离去基团，HL-R1是其共轭酸，当L为N时，HL-R1的pKa值小于或等于6，当L为O时，HL-R1的pKa值较小 在L为SOn时，HL-R1的pKa值小于等于5; R2是2至4个碳原子的伯或仲烷基，1至3个碳原子的伯烷基氨基，2至4个碳原子的伯烷基甲基氨基，1至3个碳原子的二乙氨基或伯烷氧基; 在任何或全部5-，6-和7-位上，R 3是1-3个各种取代基; 如果该化合物具有抑制蛋白水解酶的酶活性的酸性官能团，则该化合物具有碱性官能团或其药学上可接受的碱加成盐，或其药学上可接受的酸加成盐，及其制备方法， 公开了其在治疗退行性疾病中的用途及其药物组合物。